Effect of Duodenal–Jejunal Bypass Surgery on Glycemic Control in Type 2 Diabetes: A Randomized Controlled Trial

By  

OBESITY, Vol. 23, Iss. 10, 2015-10 ,pp. : 1973-1979

John Wiley & Sons Inc

Access to resources Recommend Favorite

LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo‐Controlled Trial

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 158-169

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo‐Controlled Trial

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 11, 2015-11 ,pp. : 983-990

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effects of duodenal‐jejunal bypass

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 2, 2015-02 ,pp. : 308-315

John Wiley & Sons Inc

Access to resources Recommend Favorite

Duodenal‐jejunal bypass surgery induces hepatic lipidomic alterations associated with ameliorated hepatic steatosis in mice

By  

OBESITY, Vol. 24, Iss. 9, 2016-09 ,pp. : 1938-1945

John Wiley & Sons Inc

Access to resources Recommend Favorite